A joint press release by Charité and the MDC
Researchers from Charité – Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), together with scientists from the United States and Canada, have discovered a sugar molecule whose levels are reduced in the blood of patients with particularly severe multiple sclerosis. Their discovery could pave the way for a new therapeutic approach, the team reports in medical journal JAMA Neurology*.
Multiple sclerosis, or MS for short, manifests itself slightly differently in each person – which is why some call it “the disease of a thousand faces.” Arguably the worst manifestation of MS is its chronic progressive form. Unlike the more common relapsing-remitting variant (RRMS), in which sufferers are often symptom-free for months or even years, patients with the primary progressive form of the disease (PPMS) see their condition steadily deteriorate with no remissions.
Today’s therapeutic approaches are based on the assumption that the immune system is making a mistake and waging an inappropriate attack on the layer of myelin that surrounds and insulates the nerve cells’ long, cable-like branches called axons. “In progressive MS, neurodegenerative processes steadily multiply and cause more and more neurons in the brain and spinal cord to die,” explains Dr. Alexander Brandt, lead author of the study. “However, we still do not know what exactly causes this disease variant.”
Together with Prof. Dr. Friedemann Paul from the Experimental and Clinical Research Center (ECRC), a joint institution of Charité and the MDC, as well as eleven colleagues from Berlin, Irvine and Toronto, Dr. Brandt now hopes he has shed some more light on the subject. As the team reports in their study, it appears that the simple sugar N-acetylglucosamine, or GlcNAc for short, could play an important role in the development of progressive MS. Inside an organism, GlcNAc and other sugar molecules attach to proteins on the cell surface in the form of chains. This mechanism, which is known as glycosylation, controls various cell functions by forming branched structures from these sugar chains.
“We studied 120 subjects from Irvine and were able to show that, in this particularly severe form of the disease, there are significantly lower concentrations of N-acetylglucosamine in the blood serum than there are in healthy people or patients with relapsing-remitting MS,” reports Dr. Brandt. At the time of this study, the physician was head of the Translational Neuroimaging laboratory in Prof. Paul’s Clinical Neuroimmunology group at Charité. Dr. Brandt has since moved to the School of Medicine at the University of California, Irvine (UCI) as an associate professor of neurology, but remains a guest researcher at Charité.
“In another study of 180 patients from Berlin with relapsing-remitting or progressive MS, we also found that low serum levels of GlcNAc are associated with the development of the progressive form of the disease, clinical disability and neurodegeneration,” adds the study’s last author, Prof. Dr. Michael Demetriou of UC Irvine. “This opens up potential new avenues for identifying, at an early stage, which patients are at higher risk of progressive MS and adjusting their treatment accordingly.”
The researchers hope that GlcNAc not only has potential as a suitable biomarker for progressive MS, but could also pave the way for new therapeutic strategies. “Our hope is that we can use GlcNAc and the associated glycosylation mechanism to promote myelin repair and thus reduce neurodegeneration,” summarizes Dr. Brandt. An initial, as-yet-unpublished phase I trial has just been completed with around 30 subjects, where the scientists investigated the safety of taking GlcNAc in certain doses. If it is shown to be safe, the scientists hope to be able to conduct further studies into this simple sugar’s possible efficacy as an MS therapy.
*Brandt AU et al. Association of a Marker of N-Acetylglucosamine With Progressive Multiple Sclerosis and Neurodegeneration. JAMA Neurol 2021. doi: 10.1001/jamaneurol.2021.1116
About the study
This study was funded in part by a grant from the National Institute of Allergy and Infectious Disease and the National Center for Complimentary and Integrative Health as well as the Cluster of Excellence NeuroCure at Charité.
About the ECRC
As a joint institution of the MDC and Charité, the Experimental and Clinical Research Center facilitates and promotes collaborative research between basic scientists and clinical researchers. It is a place where new approaches are developed for diagnosis, prevention and therapy, and translated to patients as quickly as possible. The Clinical Neuroimmunology Lab led by Prof. Dr. Friedemann Paul investigates the underlying causes and potential therapies for autoimmune neuroinflammatory diseases such as multiple sclerosis.
Experimental and Clinical Research Center (ECRC)
Cluster of Exzellence NeuroCure
Out-patient Clinic for Neuroimmunology
Dr. Alexander Brandt
Experimental and Clinical Research Center (ECRC)
Charité – Universitätsmedizin Berlin
t: +49 30 450 570 400
Back to Overview